A rheumatoid arthritis drug developed by Genentech proved to be effective in benefitting patients who have Covid-19-associated pneumonia, according to new late-stage clinical trial data.

Scientists resumed COVID-19 trials of the now world-famous drug hydroxychloroquine, as confusion continues to reign about the anti-malarial hailed by U.S. President Donald Trump as a potential “game-changer” in fighting the pandemic.

Swiss pharma giant Novartis will launch a Phase III trial assessing hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease.